Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge Acquires China Rights to Apogenix Brain Cancer Treatment

publication date: Jul 15, 2015
CANbridge Life Sciences of Beijing in-licensed China rights to a clinical-stage anti-TNF drug candidate from Apogenix, a German biopharma, as a treatment for glioblastoma multiforme in China, Macao and Hong Kong. CANbridge will also have an option for other indications. The drug, APG101, is a fully-human fusion protein designed to inhibit the CD95 ligand and restore the immune response against tumors. Apogenix will receive upfront and milestone payments, plus royalties at tiered, double-digit rates on China revenues. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital